Bradykinin B 2 receptor involvement in rabbit and murine models of septic shock

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 4, 1996, Pages 500-507

  Félétou, Michel ^a   Jamonneau, Isabelle ^a   Germain, Martine ^a   Thurieau, Christophe ^a   Fauchère, Jean Luc ^a   Villa, Pia ^b,c   Ghezzi, Pietro ^b   Canet, Emmanuel ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c CNR   (Italy)

Author keywords

Bradykinin B 2 receptor; Endotoxin; HOE 140; Sepsis; Shock

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; CYCLIC GMP; ICATIBANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ RECEPTOR; DRUG DERIVATIVE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR BLOCKING; SEPTIC SHOCK; THROMBOCYTOPENIA; ANIMAL; CECUM; CHEMICALLY INDUCED DISORDER; LIGATION; PATHOPHYSIOLOGY; PUNCTURE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BRADYKININ; CECUM; LIGATION; LIPOPOLYSACCHARIDES; MALE; MICE; PUNCTURES; RABBITS; RECEPTORS, BRADYKININ; SHOCK, SEPTIC;

EID: 0029665790     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199604000-00008     Document Type: Article

References (41)

1. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80.
2. Nies AS, Forsyth RP, Williams HE, Melmon KL. Contribution of kinins to endotoxin shock in the unanesthetized Rhesus monkey. Circ Res 1968;22:155-64.
3. Sardesi VM, Rosenberg JC. Proteolysis and bradykinin turnover in endotoxin shock. J Trauma 1974;14:945-9.
4. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1-46.
5. Regoli D, Marceau F, Lavigne J. Induction of B1 receptors for the kinins in the rabbit by bacterial lipopolysaccharide. Eur J Pharmacol 1981;71:105-15.
6. Wilson DD, De Garavilla L, Kuhn W, Togo J, Burch RM, Steranka LR. D-Arg-[Hyp3-D-Phe7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock. Circ Shock 1989;27:93-101.
7. Weipert J, Hoffmann H, Siebeck M, Whalley ET. Endotoxin shock in the rat: reduction of arterial blood pressure by the bradykinin antagonist B4148. Prog Clin Biol Res 1989;308: 893-7.
8. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985;6:161-4.
9. Regoli D, Rhaleb NE, Drapeau G, Dion S. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990;15(suppl 6):S30-8.
10. Rhaleb NE, Télémaque S, Rouissi N, et al. Structure-activity studies of bradykinin and related peptides: B2-receptor antagonists. Hypertension 1991;17:107-15.
11. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new, potent and long-acting bradykinin antagonist: in vitro studies. Br J Pharmacol 1991;102:769-73.
12. Wirth K, Hock FJ, Albus U, et al. Hoe 140, a new potent and long acting bradykinin antagonist: in vivo studies. Br J Pharmacol 1991;102:774-7.
13. Lembeck F, Griesbacher T, Eckhardt M, Henke S, Breipohl G, Knolle J. New, long acting, potent bradykinin antagonists. Br J Pharmacol 1991;102:297-304.
14. Pastor C, Teisseire B, Vicaut E, Payen D. Effect of L-arginine and L-nitro-arginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model. Crit Care Med 1994;22:465-9.
15. Thurieau C, Félétou M, Canet E, Fauchère JL. p-Guaninidobenzoyl-[Hyp3, Thi5, D-Tic7, Oic 8]bradykinin is almost completely devoid of the agonistic effect of HOE 140 on the endothelium-free femoral artery of the sheep. Biorg Med Chem Lett 1994;4:781-4.
16. Hasan FM, Tepliz C, Farrugia R, Huan E, Schwartz S. Lung function and structure after Escherichia coli endotoxin in rabbits: effect of dose and rate of administration. Circ Shock 1984;13:1-9.
17. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat in vivo. Eur J Pharmacol 1990;182:591-5.
18. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet J-C. Loss of vascular responsiveness induced by endotoxin involves the L-arginine pathway. Am J Physiol 1990;259:H1038-46.
19. Szabo C, Wu CC, Mitchell JA, Gross SS, Thiemermann C, Vane JR. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 1993;73:991-9.
20. Fleming I, Dambacher T, Busse R. Endothelium-derived kinins account for the immediate response to endothelial cells to bacterial lipopolysaccharide. J Cardiovasc Pharmacol 1992;20(suppl 12):S135-8.
21. Fleming I, Julou-Schaeffer G, Gray GA, Parratt JR, Stoclet JC. Evidence that an L-arginine/nitric oxide dependent elevation of cyclic GMP content is involved in depression of vascular reactivity by endotoxin. Br J Pharmacol 1991;103: 1047-53.
22. Schuller F, Fleming I, Stoclet JC, Gray GA. Effect of endotoxin on circulating cGMP in rat. Eur J Pharmacol 1992;212: 93-6.
23. Esbenshade AAM, Newman JH, Lams PM, Jolles H, Brigham KL. Respiratory failure after endotoxin infusion in sheep: lung mechanics and lung fluid balance. J Appl Physiol 1982;53:967-76.
24. Borg T, Modig J. Positive effects of prophylactic ventilator treatment on gas exchange and extravascular lung water in a porcine model of adult respiratory distress syndrome induced by endotoxaemia. Acta Chir Scand 1985;151:501-8.
25. Chang SW, Ferniak S, Voelkel NF. Beneficial effects of a platelet-activating factor antagonist. WEB 2086, on endotoxic-induced lung injury. Am J Physiol 1990;258:H153-8.
26. Worthen GS, Haslett C, Smedly LA, et al. Lung vascular injury induced by chemotactic factors: enhancement by bacterial endotoxins. Fed Proc 1986;45:7-12.
27. Opdahl H, Mollnes TE, Naess O. Effects of high dose of E. coli lipopolysaccharides on rabbit lung function, and of subsequent addition of chemotactic granulocyte activators to their isolated, blood perfused lungs. Acta Anaesthesiol Scand 1993;37:334-42.
28. Kimball HR, Melmon KL, Wolff S. Endotoxin induced kinin production in man. Proc Soc Exp Biol Med 1972;139:1078-82.
29. Katori M, Majima M, Odoi-Adome R, Sunahara N, Uchida Y. Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats. Br J Pharmacol 1989;98:1383-91.
30. Bonner H. Kinins in shock. In: Neugerbauer E, Holaday JW, eds. Handbook of mediators of septic shock. Boca Raton, FL: CRC Press, 1993:168-87.
31. Villa P, Ghezzi P. Effect of N-acetyl-L-cysteine on sepsis in mice. Eur J Pharmacol Environ Toxicol Pharmacol 1995; 292:341-1
32. Hess JF, Borkowski JA, Macneil T, et al. Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol Pharmacol 1994;45:1-8.
33. Prosser JC, Burch RM, Lowe VC, Kyle DJ, Martin JA, Noronha-Blob L. Bradykinin (BK) receptor antagonists delay the onset of hypotension and reduce mortality from endotoxic shock. Pharmacologist 1991;33:230.
34. Whalley ET, Solomon JA, Modafferi DM, Bonham KA, Cheronis JC. CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions 1992;38:413-20.
35. Bert T, Schlichting E, Ishida H, Carretero OA. Kinin antagonist does not protect against the hypotensive response to endotoxin, anaphylatoxis, or acute pancreatitis. J Pharmacol Exp Ther 1989;251:731-4.
36. Rhaleb NE, Rouissi N, Jukic D, et al. Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]bradykinin). Eur J Pharmacol 1992;210:115-20.
37. Félétou M, Germain M, Thurieau G, Fauchère JL, Canet E. Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, HOE 140 in isolated blood vessels from different species. Br J Pharmacol 1994;112:683-9.
38. deBlois D, Bouthillier J, Marceau F. Effect of glucocorticoids, monokines and growth factors on the spontaneously developing responses of the rabbit isolated aorta to Des-Arg9-bradykinin. Br J Pharmacol 1988;93:969-77.
39. Drapeau G, Deblois D, Marceau F. Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Ther 1991; 259:997-1003.
40. Griesbacher T, Lembeck F. Effects of the bradykinin antagonist, HOE 140, in experimental acute pancreatitis. Br J Pharmacol 1992;107:356-60.
41. Otterbein L, Lowe VC, Kyle DJ, Noronha-Blob L. Additive effects of a bradykinin antagonist, NPC 17761, and a leumedin. NPC 15669, on survival in animal models of sepsis. Agents Actions 1993;39:C125-7.